SOFTWARE
Blaze™
Advanced ligand-based virtual screening to dramatically increase your wet screening hit rate at a fraction of the cost
Make efficient use of your time by routinely running a virtual screen in parallel to wet screening; a virtual screen of 10 million structures just takes a few hours
Blaze has been delivering lead-like hits to our customers for almost 20 years; they have achieved hit rates as high as 30%, but what they really value is the diversity of hits returned from every Blaze screen
- Carry out biologically relevant virtual screens of large chemical databases
- Use the electrostatic character and shape of known ligands to rapidly search large chemical collections for molecules with similar properties
- Increase the diversity of your project’s leads and back-ups
- Jump into new areas of chemical space
- Find novel lead-like hits from known actives
- Replace peptides with non-peptides or steroids with non-steroids
- Achieve substantial improvements in the properties of your hits
- Search algorithm increases search speed fourfold
Blaze Cloud
Search millions of commercially available compounds using an encrypted web browser session.
Blaze workflow
Blaze V10.3 interface
Novel lead like hits from virtual screening
Flexible deployment
- Install Blaze on your CPU or GPU Linux clusters
- Deploy our Amazon-ready version of Blaze
- Access Blaze Cloud on Cresset hardware via a secure web portal
- All commands are accessible through a web-based GUI, or thorugh a RESTful web service API
- Blaze virtual screens can also be accessed through workflow tools such as KNIME or Pipeline Pilot
- Engage Cresset Discovery to carry out a virtual screening project
Blaze workflow
Blaze V10.3 interface
Novel lead like hits from virtual screening
Licensing Blaze
Testimonials from Blaze users
We sought the scientific expertise within the Cresset Discovery Services team to utilize their novel field and shape-based virtual screening methods in Blaze™, and their proprietary Electrostatic Complementarity™ technique to help identify a backup series for our target effectively and efficiently. Ultimately we identified 9 novel chemotypes that were clearly distinct to those arising from docking and pharmacophore virtual screening approaches, which was an exciting outcome for us.
Dr Zara Sands, Head of CADD and Informatics, Confo Therapeutics, Belgium
Flare gives us an excellent assessment of the potential binding of hits. We use it to triage hits from Blaze and Forge experiments in the absence of 3D-QSAR, narrowing them down to an affordable subset of the most promising hits.
Dr Graeme Stevenson, Cancer Therapeutics CRC, Australia
This is a very important and exciting project for my team so thank you for your good work. The incredibly high hit rate from the Blaze compound list is intriguing.
Anon